`
`.2\.\\S
`
`
`
`,..NN
`
`‘>mOEmE
`
`_-um_.._.-g
`
`
`w.§<moomm
`
`zOCfiUjmud
`
`cm
`
`,wmmfimficgu4<zmmpz_
`
`mm>mmm
`
`5%
`
`mmNEwa_
`
`,
`
`,
`
`.
`
`mommmooE.,,VOE
`a_.
`
`
`
`
`
`
`
`
`
`
`
`
`50
`
`6'6
`
`7‘
`TEST FOR AT
`, PERFORM AT LEAST ‘
`'
`
`
`
`LEAST ONE. TARGET FRDNI A RIDLDGICAL
`H SAMPLE DF DISEASED NIVALDIID
`
`
`
`,
`
`.
`
`52
`
`OTHER NDLIRLECLA TTs
`
`
`
`
`
`
` ' 60.
`
`
`
`DETERMINE WHETHER ONE OR MORE
`TARGETS EXHIBITA CHANGE IN
`.
`_
`_
`' EXPRESSION COMPARED TO A REFERENCE
`
`FOR A SPECIFTC TARGET
`'
`
`
` 369370R>
`
`CELLS +3505? >
`,
`'
`
`STATNTNGFOR {} .
`TARGET
`,
`"
`
`
`V IDENTIFY UP DR DOWN REGULATION BY
`
`
`
`WHETHER FOLD CHANGE IN EXPRESSION
`:
`_ FOR TARGET RELmIgBIaNDRMAL Is SIGN.
`
`IDENTIFY AT LEAST ONE NONFDISEA-SE
`
`SPECIFIC AGENT THAT INTERACTS WITH
`ONE OR MORE TARGETS EXHIBITING A
`
`CHANGE IN EXPRESSION
`
`
`
`
`
`
`.. 70
`L
`
`
`
`
`PROVIDE PATIENT PROFILE RPORT
`CONTAINING TESTAND PROPOSED
`THERAPYI’AGENT
`
`~30
`
`FIG.2
`
`
`
`
`
`j
`
`;
`
`
` HYSIOIAN INFORMATION
`PATIENTINFOMATION
` IAILTIII
`
`
`I SOME DOCTOR, MUD.
`
`MOLECULAR NAME SAMPLE PATIENT
`:
`1234 E. SOUTH ST.
`PROFILING
`LISA RANT
`
`
`
`
`
` SSNII‘. 123—456789
`INSTITUTE
`
`
`
`
`,
`.VER1.0.2:425-0
`REPORTINFORATION
`
`
`
`DATE SPECIMEN RECEIVED: 02002000 DATE REPORTED:02I09I2006 0000 00. MP-IIIMMMI
`
`DATE SPECIMEN COLLECTEIIM HOST MEDICAL CENTER: 00242000
`SPECIAL STUDIES ’ RESULTS AND INTERPRETATION
`
`TUCSON, AX 12345
`
`480423-4567
`
`INTERPRETATION:
`
`REVIEW OF PATHOLOGY SLIDES (RECEIVED FROM MAIN HOSPITAL IIICSON AZ ONE PARAFFIN BLOCK LABELED
`MIN-123 AND FROZEN TISSUE)
`
`PELVIC AND RETROPERIIONEALTUMOR: INFLAMMATOR‘I’MYDFIBROLASTIC TUMOR.
`
`100
`
`108
`104
`202
`- POSSIBLEAGENTSTHATMIGHTINTE ICTWITHCANDIDATEGfiTARGETS-i
`
`//
`
`CANDIDATE TARGET
`ASSAY“
`NFKBIA
`MICROARRAY
`~ C—KIT
`‘IHC
`PDG‘FRA
`MICROARRAY
`GART
`MICRDARRAY
`VDR
`MICROARRAY
`ADA
`MICROARRAY
`TOPI
`MICROARRAY
`HIFIA
`MIGROARRAY
`DNMTI
`MICRDARRAY
`*IHG : IMMUNOHISTOCHEMISTRY
`
`SIGNIFICANT RESULT
`(INCREASED 1.78)“
`(INCREASEDT‘Z, 93%)
`(INCREASED 4.74)“
`(INCREASED IND)“
`(INCREASED 37.30)“
`(INCREASED 5.P26)
`(INCREASED 278)“
`[INCREASED 4NI)“I
`(INCREASEDIIII)“
`
`\
`
`POSSIBLE AGENT S
`VELCADE
`GLEEVEC, SUTENT
`GLEEVEC, SORAFENIB, SUTENT
`ALIMTA
`CALCIIRIOL
`PENTOSTATIN
`TOPOTECAN, CAMPTOSAR (CPIII)
`AVASTINI SORAFENIR SUTENT
`VIDAZA (S-AZACYTIDINE)
`‘
`
`,
`
`I
`
`'
`
`** INCREASED OR DEC‘REASED ARE RELATIVE TO NORMAL CONTRLS.
`
`FIG.3A
`
`
`
`
` PHYSICIAN INFORMATION
`
` PATIENT INFORMATION
`
`
`SOME DOCTOR, MD.
`NAME: SAMPLE PATIENT
`
`
`SEX: FEMALE
`MOLECULAR
`.
`1234 ESOUTH ST.
`
`
`. Agfgfigg‘mfl
`SESTNTT TQAIEET-STRQ
`PROFILING
`
`
`
`
`¥
`-
`¥
`INSTITUTE
`
`
`REPORTINEQRNATION
`VER 1 0.242505 .
`
`DATE SPECIMEN RECEIVED 02012000 DATE REPORTED. 02H002000 CASEND MRTNN05040
`
`
`
`DATE SPEIMEN COLLECTED AT HOSTMEDICAL CENTERO012402000
`
`
`
`.
`
`, SPECIAL STUDIES
`RESULTS AND INTERPRETATION
`ADVANCED IMMUNOHISTOCHEMICAL ANALYSIS:
`ENE EXPRESSED PROTEIN
`CONCLUSION
`SPECIFICITY INTENSITY .TTARGETSTATUS‘
`
`112
`
`NEGATIVE
`HERZTNEU
`_
`NEGATIVE
`ER
`"N‘E‘G‘AT‘N,—"“_E‘—“' “" —“—'”‘“
`RR'
`POSITIVE
`SPECIFIC_2
`'
`00
`'
`TARGET
`C-KTT
`NEGATIVE
`‘
`EGFR
`00x2—~ NEGATTV‘E‘" _‘
`
`'
`
`'
`
`'
`
`.
`
`1
`
`'
`
`
`
`‘
`-
`0052
`NEGATIVE
`-
`'
`‘
`
`PDGFR
`NEGATIVE
`RNSPECIFIC
`~ CD25
`NEGATIVE
`,
`
`
`
`
`108 .
`'
`110
`'
`* 2+ IHC IN GREATER THAN 30% OF THE TUNOR CELLS HAS BEEN CHOSEN AS A CONSERVATIVE DIVIDING
`POINT TO REPORTA POTENTIAL TARGETAS POSITIYE TO HELP INCREASE PHARMACOLOGIC EFFECTIVENESS.
`
`114
`
`IINIUNOHISTOCHENICALTESTRIDTPERFORMED
`
`'
`
`.
`| LA 2
`TIT-KAPPA BETA
`THYMIDYLATE SYNTHASE
`ERCCIT (HELICASE)
`THYMIOINE PHOSPHORYLASE
`NGF
`NTAP
`NAP KI NA'SE PROTEIN
`XANTHINEOXIDASE
`
`TOPOISONIERASEI
`TOPOISOMERASEII
`.RETINOIC ACID RECEPTOR
`R X R
`ORNITHINE DECARDOXYLASE
`SDMATOSTATIN
`RASIMUTATED)
`ASPARAGINE SYNTHETASE
`
`NLI-IT
`NSH2
`CD20
`P53
`CYCLIN DI
`BCL-2
`VEGF
`
`FIG.3I3
`
`
`
`'
`
`.
`
`PATIENTINEORNATION
`
`.
`
`PHYSICIAN INFORMATIN
`
`-
`
`*
`
`
`
`
`
`
`SOME DOCTOR, NIT
`NAME: SAMPLE PATIENT
`
`
`SEX: FEMALE
`MOLECULAR
`I234 E. SOUTH ST.
`‘
`
`
`
`DUB: (gm/1974
`.
`_
`4 TUCSON,AX 12345
`
`
`PROFILING
`¥ SSNII: 123-455-6789
`, 480-123-4567
`
`
`
`
`INSTITUTE
`
`
`
`VER1.6.2:4-2‘5-08
`REPORT INFORMATION
`7
`
`DATE SPECIMEN RECEIVED: IIEIIIIIzooE DATE REPORTED: 02I09I2006 CASE NO. IIPTNoe-NIN
`
`
`1 DATE SPECIMEN COLLECTEDAT HOST MEDICAL CENTER: 01I24l2006
`
`
`
`
`
`
`
`
`
`
`I
`
`'
`
`
`
`
`
`
`
`
`
`
`
`
`'
`
`'
`
`.
`
`
`
`
`
`~
`
`
`
`
`
`
`
`
`
`SPECIAL STUDIES
`MICROAEWIEYRULTS
`18
`
`
`'
`..
`V
`.
`I
`
`m
`18
`r100
`16IIIICROAREAYANALYSIS:118 16
`
`
`
`
`
`
`
`
`,GENE
`RATIO EXPRESSION ANALYSIS
`GENE
`RATIO EXPRESSION‘ANALYSIS
`
`
`
`
`
`II-UNEEEEXPRESSED EGFR III' IIII .
`
`
`0.09II IIII- II
`ESE
`
`III- MLHI III III-
`-_- --- ZAPTE
`306 N0 CHANGE -
`
`
`
`
`III- IIILI
`INI-
`IIII IIII 3.16—-
`
`
`
`
`UNDEE EXPRESSEDI III I EVEREXPRESED I
`
`
`
`
`
`IIII III OVEREXPRESSED I.
`II I OVER EXPRESSED - I OVEREXPRESSED I.
`
`
`
`II III- II
`
`III- III HIFIA
`OVEREIIPRESSED I‘
`
`PDGFRB-_.- III III
`
`
`
`
`
`
`0.80II BECAZ III II
`sou
`
`ESTPI' II GARE III—I III
`
`
`
`
`SPARE II IIOI‘EREXPRESSED I HIFIA VII
`
`
`
`
`II III IFIA II
`
`
`III POINT .0I‘ERBIPRES‘SED I III-
`
`
`III III FDGERA-_-
`III III- II
`
`
`
`
`
`SSTRI II II ABA 5.26—-
`
`II III TOP2A III
`
`
`
`
`
`
`
`
`TYNS O-EREXPRESS D I
`III-
`I“NO CHANGE" INDICATES THAT THERE IS NO DIFFERENCE IN EXPRESSION FOR THIS GENE BEIIEENTHE TUMOR AND CONTROL
`TISSUES ATA SIGNIFICANCE LEVEL OF P<=ODOI A SIGNIFICANCE LEVEL OF P<EDDOI HAS BEEN CHOSEN SINCE GENES PASSING .
`THIS THRESHOLD CAN BE VALIDATED AS DIFFERENTIALLY EXPRESSED BY ALTERNATIVE METHODS APPROXIMATELYSS'N OF THETINE.
`
`
`
`PATIENT: SAMPLE PATIENT
`
`CASE NO. MP~TNOS-O5OAO
`
`‘I 0.0
`
`fl
`DATE REPORTED: DEMONS
`
` ' CLINICALINFORMATION
`' CLINICAL HISTORY
`
`N THEPATIENTWASDIACNOSEDWITHIRELANDORYMYOFISROBLASTICTUMORINFEB2004.ATTHATTIMEALARGE
`
`MASS WASREMOVED FROMHERABDOMEN THE PATIENT NOWHAS RECURRENT MASSES ON HER LEFT UPPER OUADRANT
`AND IN THEPELVIS. PERTHE PATIENT CHART DR SOME REVIEVED THISCASE WII H DR VON HOFF AND IT WAS AGREED
`THAT PERFORMING DNAMICROARRAYAND IHC TESTING ON THIS PATIENT MAY PROVIDE INSIGHT INTO FURTHER TREATMENT
`
`1 20
`’
`
`OPTIONS.
`
`SPECIMENSSUBMITTEO
`RECEIVED FROM MAIN HOSPITAL, TUCSON, A2,, ONE PARAFEIN BLOCK LABELED 1101-123 AND FROZEN TISSUE WITHTHE
`ACCOMPANYING SURGICAL-PATHOLOGY REPORT.
`
`122
`
`DISCLAIMER
`THESE TESTS WERE DEVELOPED BY MOLECULAR PROFILING AND THEIR PERFORMANCE CHARACTERISTICS DETERMINED
`BY MOLECULAR PROFILING IT HAS NOT BEEN CLEANED OR APPROVED BY THE DS FOOD AND DRUG ADMINISTRATION
`FDAgTHESETESTSARE PERMITTED FORCLINICAL PURPOSES AND SHOULD NOT BE REGARDEOAS PURELY
`VE TTGATIONAL OR FOR RESEARCH. MOLECULAR PROFILINC IS CERTIFIED UNDER THE CLINICAL LABORATORY
`IMPROVEMENT AMENDMENTS OFI SSS (CLIA) AS QUALIFIED TO PERFORM HIGHCOMPLEXTTY CLINICAL TESTING.
`DECISIONS REGARDING CAREAND TREATMENT SHOULD NOT BE BASED ON A SINGLE TEST SUCH AS THIS TEST RATHER
`DECISIONS ON CARE AND TREATMENT SHOULD BE BASED ON THE INDEPENDENT MEDICAL JUDGMENT OF THE TREATING
`PHYSICIAN TAKING INTO CONSIDERATION ALL AVAILABLE INFORMATION CONCERNING THE PATIENTS CONDITION
`INCLUDINC OTHER LABORATORYTESTS IN ACCORDANCE WITH THE STANDARD OF CARE IN A GIVEN COMMUNITY
`THE FINDING OF ATARGET DOES NOT NECESSARILY INDICATE PHARMACOLOGIC EFFECTIVENESS.
`
` 4...,
`
`
`ETA/2006
`7
`:
`ROBERT J; PENNY, NDPATHLOGISTAND NEDICALDIRECTOR DATE
`
`FIG.3D
`
`
`
`com
`
`mom,
`
`wow
`
`mom.
`
`
`
`mSDQEOE<>n_:.zmo_
`
`25024.10<wtmfxwZIP56mg
`zofiwmmmxm
`
`n5>._..._<m:._n_<z_
`
`
`
`wish—$52.mmmdmma
`
`03mm<mmkm_z_§o<
`
`m1...OHEdam;
`
`
`9259203amw<mm5
`
`mIH:mfxm.35
`
`szwmmaxmz_mozafo
`
`>z<mzfimmflo
`
`mE.z.mmOz<Io
`
`
`
`501$.$320505
`
`mommmfim2—Qm_..=._.zmo_
`
`v.9“.
`
`
`
`
`
`
`
`EEmVrmEOmasw2928945230
`
`
`
`
`
`
`
`Ema/Coma03mm
`
`
`
`
`
`mz_o_mm_§DmNfi<zowmmmawwdméQEfimOmZ
`
`
`
`
`
`mozzonfioo63mmw>m4mwzhO._.mwzoammm”mo_._.m_mm5¢m¢xuwmmakfimammm<me
`
`
`
`
`
`
`
`
`
`
`
`.szEQE<$350“<8
`
`
`
`
`
`..m2_ozwE8._83mREE..oz_z_2a_m>._<z<V
`
`Ezogm:
`
`mzazm
`
`
`
`..Qmmaoxmm<§<g..
`
`EEEE@3233....,.
`
`‘.mm_m<zo__55
`
`
`
`QUE
`
`5.2%
`
`
`
`
`
`.750.5025.
`
` mag$028
`
`Iomfimmm52:0
`
`
`
`
`
`
`
`
`
`
`
`
`
`«So7,\flmmfifi@2225\wngme,Vwings“:43%50
`HV20%th§..
`
`H.38memg:ENE.9ng
`
`
`
`
`
`
`
`
`
`
`EEEEEOEE
`
`ZQEEEZEEEEEEEEEEEGEEEm;.
`,_EEEQEEE
`
`.325%mm;
`
`25%Egg2220mm322:0
`
`Ema/0mm
`
`
`
`
`
`wo<l0._n._.2>Ez,m«EEOomfifiu.-mmg
`
`
`
`$2,mag?
`
`.E23“523%>E2wBEES
`
`SE353%32.48%?$23sz.
`
`<_>mafiaE52;EEESE.
`
`5%3
`EEEEEEEEEEE
`.EEEEEEZE.
`_EEEE.
`
`EEEEZEEE.
`
`lEggs.:_
`
`EEEEEEZEEEE
`
`455$:
`
`
`
`
`
`.2,EEE,BEE/mamman—EmH.wnwwioé8
`
`5.2%
`
`“Es/$2058252mm;.
`
`ambEEEZEEDEgg
`
`
`
`
`INTEGRATED
`TE VIEWS
`
`.EaEEEEEEE
`
`
`
`H.EEOEEEE_E_EEEEngEEEEEE
`
`INTEGRATED HISTORY
`ORIENTED VIEWS
`
`©.®_n_
`
`BEDS”.ma$580225.48%;
`
`2,2QZEEmagma2.9228.
`
`«g20owmdaaflfimo$2$52SE.
`QEEWgm..om:51%.Lo$55
`
`
`wiseEa
`
`
`
`
`
`megammqméa$9sz52:828
`
`=2; " ammwixawwa
`ISIIVIS
`I
`STOOL 1V3.
`' ONISSEIGOIId 30W“ I
`SOIWOHIO‘dd
`‘
`SOIINONEIE)
`
`ISTRIBUTED
`SUJECT ORI
`
`
`TomfizmmmxlwmBEBEqumason:.EaSQwEg
`92BE8,62%asécmm_(Ea.5%«EV.
`
`«Ea5&8lo02a?«E.Ea
`
`.mwzozééEEG.,SEEa3$8:me
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`N .
`
`OE
`
`r..._——__————.—4—...._~_u-u—-—-—
`
`29222222222
`
`22222222022Em.
`
`
`
`2222222(2222.522.
`
`222222222.20.
`
`
`2222222220.
`
`.
`
`222222222
`
`
`
`2.228222%;:22
`
`
`
`.2223cm:22222222222:
`
`
`2222222222222.2222222222822
`
`22222222_
`
`825%mm;
`
`
`
`
`
`Ewpwxrwhmonaawz.Q_m_owm_._<o_2:o.{sifinnunuuuunnnnuuuuunnnuun..§_{.
`
`
`
`
`202228222222222:.222223222...22222222222222.
`
`22222298.:222222222222222222222222.
`2222.222..
`
`.¥22222222222222.2222...2__222222222222
`
`
`
`
`
`
`22.222.“22.22.22222......22.222.222.22
`
`
`222222.mafia.222228.
`
`222mm22.,,.22282222;
`
`22222.22222.,_..2222222222
`
`
`,22222222222202222W22w2m.
`
`22.2
`
`
`
`
`
`
`
`
`
`
`
`
`
`222222222222222222222..22222222222..q,2222222222...2222222222
`
`
`
`
`
`22%,_.2220.
`
`
`
`”5&2599222222.23.2.58:
`
`
`
`
`
`
`
`22m.,..._
`
`.282820..
`
`mmfima02.mzme
`
`wagofiz$
`
`222.2222
`
`22222202222
`2222222222
`
`2223222222
`
`
`
`
`
`22222202222222:.2222+22w2wmmm82
`2222288.,,_‘
`
`
`
`29.225222.22m2zoo.
`
`
`
`225222222222.222.222222222222222...
`
`
`
`.222222222.2..222222222,2.202222
`
`
`
`
`
`222222222222.,..222222
`
`2222202222..22222222.222222.22
`,,
`
`
`
`.2222222
`
`
`
`
`
`
`
`
`
`
`
`
`><mm<omo§.
`
`QZEEOZmG.
`
`wQEOmHomm.
`
`
`
`.Emmzooamid.
`
`
`
`35kmHzm2m0<wz<§w0265.4535:8;me
`
`huggmf.
`
`OI...
`
`-59mm53015.,
`
`Mao.
`
`
`
`
`
`“Em,__.27:.
`
`EmfiiK..
`
`FzmzamK
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`QOE
`
`28988
`
`$2243
`
`>53;.
`
`.2.5m.
`
`(22553}:
`
`.Ema6%
`
`,WEE?
`(50:28
`
`
`
`
`
`‘
`
`3%?me
`€me
`
`
`
`$85.33:.
`
`Emzézggem.
`
`295.5%
`
`,
`
`3;?
`
`..$0ngEa
`
`Egg
`
`E5329sz50:
`
` 20.,5m2mw5
`
`
`
`
`
`mafia,$me,42a,_<5
`
`
`Emagzggem22%Egfimgroggy,..Eggmgmfimfig
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`mmNBmgzfim._<u._z_._u
`
`>m<._:m<oo>
`
`V
`
`_
`
`
`
`
`
`.mz<_u_m>In_..<z<_o_m>Im
`
`,MmmrxEmfii
`
`“$.5me
`
`
`
`wagewas)It;88225E?
`
`”ngE/Ewmo
`
`mmSAFzmfii
`
`.szmm
`
`833%M.88582%
`
`
`
`zmjkmm
`
`$8582%
`
`033%
`
`,.
`
`,
`
`mo292:0.
`
`
`
`
`
`magma.ooogmsm3:55
`
`.nur.mmv_.”&
`
`
`
`
`
`
`
`
`
`
`
`
`
`mmm<mggézmwxm
`
`EQIOE
`
`mm>mmm.
`
`”magma.,
`
`EmaE.
`
`finnefifinfl
`
`c
`
`mm<m<._.<o
`
`z.o_.m.<Nj<:m.>\m5§<z<nEmpmfim
`
`
`mmEEgot—n5.
`
`«Ema..,\Iw
`
`g
`
`
`
`.295248
`
`EEEHEE
`
`.
`
`
`
`>331;$5me
`
`$.95.28gig.
`
`
`
`age.55%:
`
`_,.smugmméfié
`
`
`zoammemwzmoEmémgs.
`
`50%$5sz\f
`
`29
`
`(K?5.9
`
`
`
`
`
`
`
`
`
`
`
`Mill
`
`|
`
`ll“: ,
`
`lllll
`.
`“I1;
`"in.
`
`
`
`mmjozmmfisfigEa:
`
`m._.<>_m&o:m:m
`
`mm<mdm
`
`mega
`
`$5E05$5V
`
`‘$.40
`
`w_m>.Ez,q
`
`m._oo._.
`
`.
`
`
`
`
`
`zmwmmflvm..E3Egg
`
`mmzzgm
`
`
`
`>53%..
`
`37E._§z_.._o
`
`392:0
`
`ma
`
`._.zmfi<n_
`
`mo
`
`
`
`
`
`
`
`
`
`ESE
`
`
`
`@253,...._.,.magma”gig
`o.a:m2%203%onoo.
`
`$53
`
`
`
`,.._,_o_zwmmwo¢.,;.
`
`
`,205%?292.3%
`
`Eofigm
`
`
`
`
`”$53ng222323......
`$22228mam
`20.53$2.925»Essa
`
`
`
`
`£20925%585%awwémmg
`
`$8ngm3“.E
`
`$2,
`
`$938
`
`Hmggmm
`
`
`
`$23:2
`
`£2,123
`
`_._5_z_.5$§<w
`..2Gigi
`
`$23SEE;
`
`._,558,350%,
`
`gags
`
`5.85:5
`
`
`223222222222222“22.20222.,”m2222
`§§$33,2222
`
`
`..222222222222
`
`
`
`
`
`mmsg
`
`EEK
`
`
`
`
`
`
`
`
`
`
`
`
`
`.._,.Cwmmzo_t._.o<ma
` s
`
` ,.mmngtho/Em,mumI.EUEw—z
`
`Ezmfifiw._.zm:<n_
`
`
`imam—2
`
`
`
`magmaI
`
`,
`
`" PR MPI
`HRS,Mm
`E
`_WPWON
`
`‘
`
`DIAGNOSIS,
`
`PROGNOSI‘
`I
`TREATMEN
`
`DIAGNOSIS -
`PROGNOSIS
`* TREATMNT »
`
`omw<m.zo_._.<§m0mz_n6meSEZ
`
`
`
`
`
`mz.,o_om§mej<20wmmn__
`
`
`
`
`
`
`
`EEEEEEI,
`
`.EEEEEEEEEEEEEEEESBEEQEEEEEEEEEEEEE
`
`
`EEEEEE.EEEEEEEEEEEEOZEEEEOEE
`
`EE
`
`EEEE
`
`EEEEEEEEEE
`EEEEEEEEEEEE
`
`EEEEE
`
`
`
`E228EEEEEO.
`
`EEEEE
`
`EEE
`
`EEEEE
`
`EEE,.,
`
`EEEEEEEEEEEEE
`
`EEEEOEEEE
`
`EEEEEEESEEEEEQNEEEEEEEEENEEEEEEEEEEO
`292N256
`
`
`
`
`
`IEEEEEEEEEEEEEEEEEE
`
`IEEEEEEEEEEEEEEE__EEEEEEEEEEE
`
`EE.EEEEEEEEEEEEEEZEEEEéEEEEmEEEEEE.o
`
`EEEEEEEEEEEE
`
`IEEEEEEEEEEEEE
`IEEEEEEEEEEEEEEEE
`
`EEEEEEEEEEEE
`
`NEHEEZE
`
`IEEEEEEEEEE,
`,..EEEEEEEEEEEEEEEEEEEEE.
`
`
`
`
`
`EEEEEEEEEE
`EEEEEEEEEEE
`
`EEEEEEEEEEE
`
`EEEEEEEEEEEE
`
`EEEEEEEEEEEEE
`
`
`
`EEMEEEEEEEELWEEEOE
`
`
`
`EEEEEEEEOEEEEEEEEEEEEWEE.MEEEEEMEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEE
`
`
`
`
`
`
`
`
`
`
`
`
`
`IIIIIIIIIIIIIIIIIII
`
`
`
` IIIIaIIIIIIIIIMNIIIIIII.IIIIIIIIIIIIIIIIIIIIIEEIBZI
`
`
`_EII.nIIIIIII.._mIIIIIIIIIIIImIIIEIIIIIIIIIIIII.
`
`
`
`IIIIIIIII.IIIIIIIIIIIIIIIIIOzIIInIomnI
`
`
`..IIIIIIIIIIIIIIII
`
`
`HHIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIEIIIII
`HmIIIIIIIIIIIIIIIII|IIIZII$561538
`
`
`IIIIIIHHHHIIIIII.IIIIIIIIIIIIIIIIIHIIIIIIIIII
`
`
`
`HHHIIINIIIIIIIIIIIIIIIII
`
`HUIIIIIIIIIIIIIIIIIIIII
`HUIIIIIIIIIIIIIIIIIIII
`
`
`Isa?IIIIIIIIIIIIIIIIIIIIUIIIIIIIIIIIIIIIIIIIII
`
`
`HHIIIIIIzIIIIIIIIIIIIII
`
`
`HIIIIIIIIIIIIIIIIIIII
`
`
`
`
`
`IIIIIIIIIIIIIIII.IIIIIII
`
`IIIIIIIIIIIIIIIIIIIIIIIII
`
`IIIIIEIIIIIIIIIIIIIII
`
`BQ@9%“aE.EE.
`
`$32865.
`
`
`
`,
`
`III
`
`
`
`
`
`
`Hill!.3IIIIIIIIIIIIIIIIIIIIIIIIIIIIII
`
`.IIIIIIIIII
`...anI
`
`
`
`HUMVaEEEnoHE553ch
`
`2%
`
`Hmém$2._.3N5552EWIIHWHIIIUILNHEE“22:.HwHEE:5620835
`
`
`IIIIIHTEQmg,7wwwmmofiwfi
`
`WHHE5.52,Nzogzémo.
`
` gig.
`
`33%.
`
`EdazwfifiaémE5mS._._.~mz_
`
`...__.-If__..H_w02_.=u_omm
`.42”,35:3..
`
`
`
`.es2gm?2:52&5$53050:
`
`
`
`BQMy9am“aEmIha:gag.”$.QO$98ng£7:E):9.a:I
`
`
`
`:mama”QLMIm8
`
`
`
`
`
`
`
`.HHHHHHHHHHH-
`
`
`.H|._HH..HHH.HH..,.IHHHHHH
`
`....lHHHHHHH
`
`.
`
`
`
`
`IHHHHHHHHHHHHHHHHHHHHHHHHH....HHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
`
`
`lHHHHHHHHHHHHIHHHHHHHHHIHHHHHHHHHHHHHH
`
`HHHHHHHHHHEHHHHHHHHH.,
`
`..,HHHHHHHHHHHHHHHH
`
`
`
`.HHHHHHHHHHHHHHHHH.HHHHHH
`
`
`.HHHHHHHHHHHHHH..
`
`
`_|HHHH.EH.HuHHHHHHH
`
`_IHHHHHHEHHH.HHHHHH
`
`
`
`HHHHHHHHHHHH
`
`HHHHHHHHHHHHHHHHHa..:
`
`HHHHHHHHHHHHHHHH_.....H.HHHHI...
`
`....HH.H.HHHHHHH_HHHHHHHHHHHH
`
`
`
`HHHHHOOHHHHEHHQHHHHHHHHHo.HHHHHHHac.9332HHHHHBHHH.HHHHHHH
`
`
`
`HHHHHHHHHHHOoHHHHHHHHH@.HHHHHHHHHOHHHzHHHHH.HH
`
`HaHHHHHH
`
`
`
`HHHHHHHHHHHHIHHHH
`
`HmEHHEHHHEHH—
`
`HH3%HHHIHQH
`
`
`HHBHHHHQHHHHHEH
`HHSHHHHHHHHHH
`
`
`
`
`
`
`
`1%....@flEDP—52.wzzmommmisomHOEB@99%.@
`
`
`
`.HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
`
`
`
`
`
`
`
`
`
`
`
`
`
`mwgéfig..0%E453?
`
`
`@@@9%.@,wwfi3mg3...
`
`
`1m:3225..ExamwmmoaxgmaE2E}:3WEa.
`
`E.§E
`
`
`
`mwozm6901:;we55m
`
`.._zo_.Emm&Ez_
`
`
`
`E228yafimgfiz
`
`Zecémonszfizzu
`
`,.
`
`
`
`;.$9935.25
`
`
`
`‘.7.3:_2m3mmzw§am¢m
`
`
`
`Juneau?
`
`
`
`
`gi
`
`MICROARRAYANALYSIS
`"
`RRRIRRHRRRRRRRRRRRR R-iImRRRTRRRIRRR RRRIRRRRRRRRRRRRRRRR
`,
`RRRTIRRRRRRRTRRR- RRTIIRRIRRRI- IRRIIIRIRIRRRRI-
`5%AK
`WT -[RRIRRRRI-
`RRRR I TUTTI-GENES 71
`2C:- C.)at:Emm
`g93
`MNROTfigITIRTRI-IIIIII
`.
`.
`EQ?“
`-RRIR- RRRIRRI R
`;~13E::E3?I
`IRRIIRRIRRRRI- TlgTTTIIITTIIIDII
`2:TO
`RRR l---1
`Q
`IRRRRRRRRRR- IRRIRIR
`:1-
`g
`MRRRRRRR-
`aE EE;i E
`RRIIRRRRR RR-
`03Amt-11
`I-IRII,
`I.
`-
`’m."% x—yc)“-c:73:31.11.LlIIII<11:
`II
`g%4%.
`._L.
`FF.
`m c;"—35%x,F0mr‘fi‘
`.asmm1—K:
`I'-.im%‘ml‘fi
`
`z%o%.
`‘1-%
`g:. H 4
`E4 I
`
`
`
`5'!
`
`C:
`[TITS]
`BET
`
`[MT
`
`
`
`"=1%STEa:.53.‘
`
`.
`
`(5‘3
`
`a
`
`
`
`E5—?
`I-
`
`-
`3%
`
`E
`
`éIn E:E:
`
`4!:~81 i §:s%%:~r-—130*Iggl
`2-zo6:}: C'}~=2:.42-—
`G)(I)mm
`2>m «I
`ZZZOco.("an2529-(7.,cwfi'f“r—ru
`rruw—u
`.fl.5‘
`gar-I
`xv»?-A“
`
`.4
`
`...I
`
`EE
`
`
`
`4-—E
`
`E
`E’s“
`
`.
`-
`_,
`-
`'
`IETTIITOIIIIITIIIRIRI{MRIIITIIIIRT‘ITRTTWAIMITRI'
`Em?dEEEI-IIIIIIIIIIIIIIII
`I'RIRRIRRRRIR—
`.
`II
`4 123E NORTH ST
`MOLECULAR SETS
`FARGO 111312345
`v
`R4
`333453-7890
`v PROFIUNG SDTI': ImIiTR
`INSTITUTE 1DATESPEDIMEN RECEIVED.
`CASENO.TITPTITTOSIB
`DATE REPORTED.
`.
`DATE SPECIMEN COLLECTEDAT HOST MEDICALOCENTER;
`
`PAGE SOFT
`
`4
`
`E fi
`
`-7»%NT%61’.
`
`g
`
`..OI-Q1%
`
`.
`
`:14g
`
`
`1:3%%‘33.
`
`,i E§§§%§§%%%§§:$
`
`
`
`.(‘32:?)
`
`a
`
`:0Do
`
`‘n5%*:age:
`
`'
`‘
`
`“ROOT-TAHOE INDICATESTHATTHERE ISNODTFFERENCEINEXPRESSIONFORTHSGENEBETWEEN
`THE TUMOR AND OONTRDLTISSUES ATA SIGNIFICANCE LEVELOF P<=0.DOT. ASIGNIFICANCE LEVEL
`OF P<=DTID1 HAS BEEN CHOSEN SINCE GENES PASSINGTHIS THRESHOLD CAN BE VALIDATED AS
`DIFFEuITENTIALLYPRESSEDBYALTERNATIVEMETHODSAPPROXIMATELY9.5%OF'THETIME
`
`FIG.20
`
`
`
`
`
`
`4444444444444444444...I._444444444444444444444402440444
`
`44,4.4444444II4444444:
`
`.44444444445444.4444:444444444444454.452.
`
`
`
`
`444,4449%44ENE@fl
`
`
`
`444444.44444444444444440444444
`
`44444444@444.44444444444444444444.§
`
`
`
`444424404444
`
`
`
`4444444444.444444444444444
`
`
`
`4404444444444444
`
`
`
`44544442.444
`
`
`
`4444.54.44440444444444,
`
`022044444
`
`4444444444..
`
`4444444444444
`
`4444444444444444444..
`,
`444444444
`
`
`
`.444444444
`
`4.4444444444442444
`
`mflU44444444444
`
`
`
`mflu44444444444
`
`DU44444444444
`
`ufl444444444444
`H44444444444444
`
`IU4444444444444_
`
`uflU444444444
`uflu444444444444
`
`
`EMU4444444444444444444444U4444444444
`
`
`
`EMU4444444444444444444
`
`
`umHu4444444444444444444444444444444
`
`flu4444444444444444
`4444444444
`
`NU4444444444.V.4444
`
`
`NH444444444444444444444444
`
`
`
`
`444444444444444444444
`
`4444444444444444444
`
`I11111!...th
`
`4444:444mdza444444
`
`
`
`4444444444. V
`
`
`
`
`
`
`
`444444.4444434444444
`
`.44444444444444
`
`20.444444444424494.
`
`4444444444444444444.444
`
`44444444444444
`
`44444444444444
`
`m4444444444544.
`44444444444444
`
`
`
`
`
`
`
`
`
`
`
`444444444444444.444444844444444444.44444444.:4.4.4-
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`mozmomx38%?.$582
`
`
`
`$8.,582
`
`
`
`Ed.:53a
`
`
`
`“2.282
`
`IIIIQBya
`IIm
`V
`IIIIIIEI
`
`mmqmfléa:.0Emmézfimfi
`5335352.A_§V._Egg62%;:va.
`
`
`
`
`
`
`oémmmgxmmzmwEma?—gmfiw.Zggawwmgézmw
`32%:wag5a.53:02.0ENEazaxwiWig
`.”Egg;o$ng.,it‘_
`$3302032%o539%Eggs2;...
`
`
`
`..,.._Eadie?5&3?“go.§g5.8%?2%?$05330;
`Egg?5%a2$32on23%.Em.“HE
`
`
`gugmgééggggagiwafimgga
`ENE..SEmafia,#2ng
`
`
`
`
`@2525“£8.ng2.033
`@2552ggmagwm
`
`3.
`
`.0
`
`‘5
`3|
`
`
`
`$1gggamggmwmmswm25%52E»Ea:a$3me
`
`.nWwEfigau
`.Eggalmg.‘
`
`
`
`
`Hammad;MNOE.,,.,,mafia-mg.
`
`:
`
`
`...,..1,,,
`..
`.HHHHHHHHm;HHHHHHH:I
`
`
`H2220,,H2H3.82H.a:$832%EHWHOHHHHHHHHHHHHHHHHHHEH:m22HmHHammmHquomoEEons:
`
`5%:HgmagwQ5HHHZHZHHHHHHHHHHEHOHHHHHHHOHHHHHEEHHeHHHHHHHHHHHEEa
`
`:HE.HHHHHSHSHHHE
`HHEHHHHHHHHHHHQHHHHWHHHHHEHHH233mfg;..HHHH
`
`
`55HH5%GREG“:OHmgswmmHEHOE.,HHHSHH
`
`EnemiesmafiaHHHHHHHHHHHHOEHHHHEHHE
`
`.HaHI:QHHHHHHOHHHHHHHHHHQHO$22H:aHz2Hm.....HHHHH.H
`HHEHHHHHHHEHEHH20%QHHHOQHHHHEHHHHHHHEm
`
`
`H250:HHHHHHHHEHHHH:HQHHHHHOHHHHHHHHHHHMHHHHQHH.
`HHHH:Hg:HHHHHHQHHHHEHHHHEEH9.5%HQ11:.
`.HHDHHHHHHH32HimOHHHHHQHHHHHHHHHHHHOHHHHH
`
`
`
`ale—N
`
`CiV—‘mV—‘T‘TJWN‘WV—vw
`
`N
`
`
`
`1meon?meHHHHHH”HEm
`
`
`
`HHHHHI‘HHHHHHHZHHH”HHHHHHHHHOHHHHHHHHHQH
`
`
`
`
`
`
`
`
`
`.Hsomm29%Ha.HagmHHHHHmHEEHHE”HEEEHHHmanm
`
`
`
`$23582:meH.H
`
`
`
`
`
`
`
` .2%”302,53525me..
`
`
`
`
`
`
`
`§EEE.EEEEEEEEEEEEE.
`
`EEEE.EEEEWEIEEEEEEEEEEEEEEEEEEEEEEEEEEEEEBEQEE
`
`
`
`
`EEEEEEEEEEEEEEEE.EEEEEEE§023.6%EEEEEEEEE..EuEEEEEEEEDEEEEEEEEEEEEEEEEEEEEEEEEEEE.a,,EEEEEEEEEEEEEEEEEEEEEEE
`
`
`
`
`
`
`..%EEEEwE
`EEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEE..EEE-V
`
`
`
`.EEEEEEEEEEE
`EEEEEEEEEEEE
`
`EEEEEEEEEEEE
`EEEEEEEE
`
`EEEEEEEEEEEEEEEEEEE
`
`ESEEZE
`
`EE
`
`EEEEEEEE
`EEEEEEEEEEEE_.EEEEEE
`_EEE
`
`EEEEEE
`
`EEE
`
`EEEE
`
`DUEEEEEE39$0;
`
`EmmmumEEOEEEOEEEDE5%vvmEEEEo29m.8ME:v.53.
`
`
`
`
`
`
`
`.
`
`.32%E02
`
`fl.EEEEEE.DEEEE-
`
`EEmmeEEm:EOE
`
`
`
`
`
`
`
`
`
`
`
`
`image mm.CW.—mugingham—g.
`fl.,
`
`3%53%Eggoz_,__u_oma
`5%“E52.
`
`52533,mi.5%”0520.misoflos.
`
`
`
`;m5:$meon
`
`2&5;th$93.8EOE.vw.
`
`
`
`$20552«zwaommmga
`
`
`
`..quomos.
`
`
`
`”Emmmumm><mm<o5§mEmmegaEgg
`
`@9@@.%“amflfim53%fig.
`
`_a:Egg”3%.232EE,Egm"
`
`
`
`.33?“$ng52.ogmwfizgzfi
`
`
`
`
`FIG. 26A
`
`Tumo r Type
`
`Adipose tissue,
`if not available use
`Adrenal Cortex (18)
`fibroblast (1)
`Adipose (13)
`biomarker
`biomarker
`biomarker
`tumor
`flagged as
`flagged as
`flagged as
`type
`target
`target
`target
`_-__—__
`—__—__
`—_—___
`—_—___
`—_—___
`—_—___
`
`—_—___
`—_—___
`—__—__
`—_—___
`
`—__—__
`—_—___
`
`Adrenal Gland (1)
`biomarker
`flagged as
`target
`
`0.00%
`0 00%
`0.00%
`0 00%
`0.00%
`0.00%
`33.33%
`0.00%
`0.00%
`0.00%
`0.00%
`0.00%
`0 00%
`33.33%
`0 00%
`0.00%
`33.33%
`0.00%
`0.00%
`
`1
`
`1
`
`1
`
`Adrenal
`Gland —
`Medulla (15)
`biomarker
`flagged as
`target
`
`
`
` W
`
`
`
`Appendix (5)
`biomarker
`flagged as
`target
`
`,_1
`
`1
`
`1
`
`0.00%
`8 33%
`0.00%
`0 00%
`0.00%
`0 00%
`16.67
`0 00%
`0.00%
`33.33%
`0 00%
`0.00%
`25.00%
`0.00%
`0 00%
`0.00%
`8 33%
`0.00%
`8.33%
`0 OO‘V
`
`2.22%
`15.56%
`0.00%
`0 00%
`0.00%
`0 00%
`67.67%
`0 00%
`4.44%
`22.22%
`2 22%
`4.44%
`17.78%
`2.22%
`0 00%
`0.00%
`6 67%
`0.00%
`15.56%
`0 OO‘V
`
`W
`
`,_1
`
`7
`
`Total Number of ICH
`Biomarkers Flagged as
`Taxget for Tumor Type
`Samles
`
`30
`
`100.00%
`
`4
`
`100.00%
`
`56
`
`3
`
`100100%
`
`45
`
`100.00%
`
`12
`
`100.00%
`
`
`
`Bladder (D
`
`Blood Vessel Vain (4)
`
`Bone (2)
`
`Brain (2)
`
`Breast (99)
`
`Cartilage (5)
`
`FIG. 26B
`
`
`
`
`
`Bone if you have it
`if not Cartilage (1)
`# of times
`biomarker
`biomarker
`biomarker
`tumor
`biomarker
`flagged as
`flagged as
`flagged as
`target
`target
`target
`type
`flagged as
`9 81%
`_—___ _
`_—___ 9.26%
`_—___ 0.27% _
`___—___
`___—___
`___—___
`
`
`
`biomarker
`flagged as
`1
`
`19
`
`biomarker
`biomarker
`flagged as
`flagged as
`tumor
`target
`target
`type
`_—
`_—
`_—
`_—
`_—
`_—
`
`_—
`_—
`_—
`_—
`_—
`
`_—
`_—
`_—
`
`_—
`
`_—
`__—
`
`
`
`
`
`___—___
`___—___
`___—m
`___—___
`___—___—
`
`___—___
`___—___
`___—___
`
`___—___
`___—___
`___—___
`100.00%
`2
`100.00% m 100.00%
`100.00% _100.00%
`
`
`
`tumor
`type
`0.00%
`10.53%
`0.00%
`0.00%
`0.00%
`0.00%
`10.53%
`0.00%
`0.00%
`15.79%
`0.00%
`0.00%
`21.05%
`10.53%
`0.00%
`0.00%
`26.32%
`0.00%
`5.26%
`0.00%
`
`
`
`FIG. 26C
`
`
`
`Dendritic cells can be
`found in skin, the spleen,
`lymph node. Let’s get
`Mike Bittner’s take on site Difficult origin to define.
`of origin (1)
`Try skeletal muscle (1)
`# of times
`biomarker
`biomarker
`'
`flagged as
`flagged as
`target
`target
`
`Colon Sigmoid (1)
`# of times
`biomarker
`flagged as
`target
`
`Endometrium (3)
`# of times
`biomarker
`'
`flagged as
`
`Esophagus
`biomarker
`flagged as
`
`Colon (6D
`biomarker
`flagged as
`target
`1
`32
`
`1 1
`
`38
`
`
`
`Cervix (10)
`
`tumor
`type
`0.00%
`9.38%
`3.13%
`0.00%
`0.00%
`0.00%
`12.50%
`0.00%
`6.25%
`21.88%
`3.13%
`3.13%
`6.25%
`6.25%
`0.00%
`0.00%
`6.25%
`0.00%
`21.88%
`0.00%
`100.00%
`
`
`
`biomarker
`flagged as
`target
`
`31
`
`4;
`
`NNr—‘r—‘QN
`
`32
`
`
`
`1——————————
`5 ——————————
`40 ——————————
`——————————
`3 ——————————
`26 ——————————
`2 ——————————
`3 ——————————
`——————————
`20 ——————————
`——————————
`39 —————————-_
`——————————
`100.00%
`100.00%
`100.00%
`100.00% n 100.00%
`
`212
`
`
`
`FIG. 26D
`
`Kidney (14)
`biomarker
`flagged as
`target
`
`tumor
`type
`
`Larynx (3)
`biomarker
`flaggedas
`target
`
`type
`
`Liver (1)
`biomarker
`flagged as
`target
`
`tumor
`type
`
`Lung (74)
`
`biomark
`
`type
`
`Gallbladder (5)
`Fibroblast (D
`Fallopian Tube (3)
`biomarker
`% in
`biomarker
`biomarker
`% in
`% in
`flagged as
`tumor
`flagged as
`flagged as
`tumor
`tumor
`target
`type
`target
`target
`type
`type
`———
`——-
`——-
`——-
`000%- 0.00%
`0.00%_ 0.00%
`11.11%_ 6.25%
`0.00%_ 0.00%
`0.00%_ 0.00%
`11.11%_ 12.50%
`0.00%_ 0.00%
`11.11%_ 0.00%
`
`S (9)
`% in
`tumor
`type
`0 00%
`0.00%
`0.00%
`0 00%
`
`0.00%
`0 00%
`21.43%
`0 00%
`10.71%
`17.86%
`0 00%
`0.00%
`3 57%
`0.00%
`0 00%
`0.00%
`17.86%
`0 00%
`28.57%
`0 00%
`100.00%
`
`1
`
`1
`
`1
`
`--—
`--—
`000%- 0.00%
`__—
`29.41%_ 30.95%
`3
`__—
`__—
`17.65%_ 16.67%
`3
`
`5.88%
`
`2.38%
`
`1
`
`5
`
`1
`3
`
`1
`
`Lymph Node (9)
`% in
`tumor
`biomarker
`type
`flagged as
`0.00%
`0.00%
`27.27%
`%
`
`2 6
`
`0.00%
`0.00%
`0.00%
`0.00%
`0.00%
`22.73%
`0.00%
`4.55%
`9.09%
`0.00%
`0.00%
`0.00%
`4.55%
`0.00%
`22.73%
`0.00%
`100.00%
`
`5 12
`
`1 5
`
`22
`
`0.00%
`
`0.00%
`
`1.79%
`
`_—__
`25.00%
`0.00%_ 24.55%
`_—__
`
`0.00%_ 13.39%
`1.3
`0.00%
`4%_
`
`34
`
`28
`
`52
`
`0 00%
`
`25.00%
`8.33%
`
`8.33%
`
`
`__—
`0.00%_ 0.00%
`
`
`
`
`__—
`__—
`“-
`—_—_—_—__-I
`0.00%_ 0.00%
`__—
`_—__
`—_—_—_—___
`_—__
`
`
`
`FIG. 26E
`
`(40) W as)
`
`a)
`
`Prostate
`(a
`
`tumor
`flagged as
`tumor
`flagged as
`tumor
`flagged as
`tumor
`flagged as
`tumor
`flagged as
`tumor
`flagged as
`tumor
`flagged as
`type
`target
`type
`target
`type
`target
`type
`target
`type
`target
`type
`target
`type
`target
`____—_——___ 5
`“_____———_-_ 2
`_____—_——__
`____———____
`____———____
`____———____
`______—_——_ 3
`_____—_——__
`____—_——___ 1
`mm 4
`_____———___
`mm 1
`mm 4
`——————————-
`_____—_——__
`____———____
`8.70%
`14
`
`biomarker
`
`%in
`
`biomarker
`
`%in
`
`biomarker
`
`%in
`
`biomarker
`
`%in
`
`biomarker
`
`
`
`biomarker
`
`
`
`
`
`biomarker - biomarker
`
`flagged as
`target
`
`3
`
`25
`
`____———____
`mm 2
`____———____
`
`
`
`
`
`FIG. 26F
`
`(6)
`
`Salivary Gland (5)
`
`Sinus tissue (1)
`
`Skeletal Muscles (2)
`
`Small Intestine (4)
`
`smooth muscle (3)
`
`Smooth Muscle such
`as smooth muscle from
`the intestine Without
`the epithelium, ditto
`for the uterus
`ie no endometrium (1)
`# of times
`biomarker
`flagged as
`
`_____
`
`
`biomarker
`biomarker
`flagged as
`biomarker
`flagged as
`target
`flagged as
`target
`___—
`___—
`___—
`___—
`___—
`___—
`___—
`___—
`___—
`
`tumor
`type
`20.00%
`8 00%
`0.00%
`0 00%
`0.00%
`0 00%
`12.00%
`0.00%
`4 00%%
`16.00%
`0 00%
`4.00%
`16.00%
`0.00%
`0 00%
`0.00%
`12.00%
`0 00%
`8.00%
`0 00%
`100.00%
`
`0.00%
`20.00%
`0.00%
`0 00%
`0.00%
`0 00%
`20.00%
`0.00%
`0 00%
`20.00%
`0 00%
`0.00%
`20.00%
`0.00%
`0 00%
`0.00%
`20.00%
`0 00%
`0.00%
`0 00%
`100.00%
`
`5
`
`tumor
`type
`
`___—
`___—
`
`___—
`___—
`___—
`
`.0
`
`_27.27%
`_____
`_____
`_____
`_____
`_____
`_____
`_____
`_____
`_____
`
`___—
`
`_____
`_____
`
`___—
`“__-
`
`
`
`FIG. 26G
`
`Stomach (6)
`
`Synovium (1)
`
`Tendon (1)
`
`Testis (1)
`
`Thymus (2)
`
`Smooth muscle such as
`Uterine wall but not
`uterine lining i.e., not
`endometrium (1)
`# of times
`biomarker
`flagged as
`
`biomarker
`flagged as
`
`biomarker
`flagged as
`target
`
`biomarker
`flagged as
`target
`
`Synovium or
`joint lining tissue (1)
`# of times
`biomarker
`flagged as
`target
`
`
`
`
`
`
`
`
`
`
`20.00%
`0.00%
`20.00%
`
`1
`4
`1
`
`5.88%
`23.53%
`5.88%
`
`1
`
`0.00%
`20.00%
`0.00%
`
`0.00%
`0.00%
`0.00%
`
`
`
`5 100.00%—
`
`100.00%
`
`100.00%
`
`100.00%
`
`tumor
`type
`40.00%
`0 00%
`0.00%
`0 00%
`0.00%
`0.00%
`40.00%
`0.00%
`0 00%
`20.00%
`0.00%
`0 00%
`0.00%
`0 00%
`0.00%
`0 00%
`0.00%
`0.00%
`0 00%
`0.00%
`100.00%
`
`
`
`FIG. 26H
`
`
`Overall
`
`Thyroid (4)
`Uterus (3)
`Uteruszcorpus (10)
`biomarker
`
`flagged as
`_______78_4.5%
`________—
`_______—_
`————————-
`________—
`_______-_-_
`_______—-_
`mm.
`mm
`mm
`_______—_
`________—
`________—
`
`_______—_
`________—
`
`
`
`
`
`
`
`
`
`_____—__-_
`__0.00%_1_12.50%“—17.78%_224
`_______-_ To-oisomerase II al-ha
`m "in—__—
`_ _____
`_ _—_—-_
`
`
`
`
`
`
`
`
`
`
`Adipose (13)
`# of times
`biomarker
`flagged as
`target
`
`Thmor Type
`Adipose tissue,
`if not available use
`fibroblast (1)
`# of times
`biomarker
`flagged as
`target
`
`FIG. 27A
`
`Adrenal Cortex (18)
`# of times
`biomarker
`flagged as
`target
`
`Adrenal Gland (1)
`# of times
`biomarker
`flagged as
`target
`
`Medulla (15)
`# of times
`biomarker
`flagged as
`target
`
`Appendix (5)
`# of times
`biomarker
`flagged as
`
`
`
`target
`
`3 _—_—_—_—_—_ — —_—_—_—_—_—_— —
`
`12
`
`12 31
`
`1
`
`1
`
`321 14
`
`1 241 1 12 31 13 31 2
`
`1
`
`>—‘>—‘>—‘4;
`
`,_1
`4
`
`2
`
`3
`
`3
`14
`
`5
`
`N\l
`
`2 143
`
`1
`
`1
`
`1
`
`1
`
`1
`
`11
`
`1
`
`1
`
`11
`
`1
`
`4
`
`1 1 7 27
`
`10
`
`1
`
`1 7
`
`14 4
`
`3 4
`
`,_1
`4
`
`2
`
`14
`
`1N
`
`35
`
`3335;
`3233?"
`328%
`.
`a
`.
`o
`0.82% — 0.000
`1.61%)
`0.00%
`4.92% — 0.00% —— 0
`000A)
`0.00%
`— 0.00% — 0.004 ——.
`0.00%
`645%
`0.00% — 0.00%
`484%
`0 00%
`0.00% — 0.00%
`0.00%
`0.82%
`— 0.00% — 0.004
`0.00%
`0.00%
`— 0.00% — 0.00%
`1
`0.62%
`1.61%
`0 82%
`0 00%
`0.00%
`0.00%
`0.00%
`__
`5.74%
`10.00%
`5.59%
`——
`0 00%
`0 00%
`0 00%
`1.64%
`0.00%
`4.97%
`0.00%
`5.74%
`0.00%
`5.59%
`0.00%
`8 20%
`0 00%
`8 70%
`0 00%
`4.92%
`0.00%
`0.62%
`1.61%
`0.82%
`0.00%
`0.62%
`3.23%
`0 00%
`0 00%
`0 62%
`0 00%
`0.00%
`0.00%
`0.00%
`0.00%
`0.00%
`10.00%
`0.62%
`1.61%
`0 82%
`0 00%
`2 48%
`3 23%
`0.00%
`0.00%
`0.00%
`0.00%
`5.74%
`0.00%
`0.00%
`4.84%
`0 00%
`0 00%
`0 00%
`1 61%
`0.00%
`0.00%
`0.00%
`0.00%
`0.00%
`0.00%
`0.00%
`0.00%
`0 82%
`0 00%
`1 24%
`1 61%
`3.28%
`0.00%
`3.73%
`0.00%
`0 00%
`0 00%
`0 00%
`0 00%
`3 28%
`10.00%
`1 86%
`1 61%
`0.00%
`0.00%
`0.00%
`0.00%
`0 00%
`0 00%
`0 00%
`0 00%
`2 46%
`10.00%
`5 59%
`4 84%
`0.00%
`10.00%
`1.86%
`3.23%
`3 28%
`0 00%
`8 70%
`1 61%
`0 00%
`0 00%
`0 00%
`0 00%
`0.00%
`0.00%
`0.00%
`1.61%
`0 82%
`10.00%
`3 11%
`6 45%
`3.28%
`0.00%
`0.00%
`0.00%
`0.00%
`0.00%
`0.00%
`0.00%
`0 00%
`0 00%
`0 00%
`1 61%
`0.00%
`0.00%
`0.00%
`0.00%
`0.00%
`0.00%
`0.00%
`3.23%
`0 00%
`0 00%
`0 00%
`6 45%
`1.64%
`0.00%
`4.35%
`1.61%
`0.00%
`0.00%
`1.24%
`0.00%
`11.48%
`10.00%
`1 24%
`1 61%
`0.00%
`0.00%
`0.00%
`0.00%
`0.82%
`0.00%
`0.62%
`1.61%
`1 64%
`0 00%
`2 48%
`3 23%
`0.00%
`0.00%
`1.86%
`0.00%
`1.64%
`0.00%
`4.97%
`4.84%
`0 82%
`0 00%
`2 48%
`1 61%
`3.28%
`0.00%
`2.48%
`0.00%
`3.28%
`10.00%
`2.48%
`1.61%
`3 28%
`10.00%
`4 35%
`4 84%
`0.62%
`0.00%
`7.45%
`0.00%
`0.00%
`0.00%
`0.00%
`4.84%
`0 00%
`10.00%
`0 62%
`1 61%
`0.00%
`0.00%
`0.00%
`0.00%
`2.46%
`0.00%
`0.00%
`3.23%
`
`_4.10‘V _ 0.00% _ 0.00% _1
`1.61%
`
`246W: — 0.00%
`0.62% — 0.00%0
`0.00% _ 0.00% _ 0.00% _ 0.00% _ 0.004)
`
`
`
`
`
`4 ,
`
`_1
`
`2 5
`
`11
`
`N
`
`10
`
`3
`
`_ _—_-
`
`,_1
`
`,_1
`
`2
`
`__—_ ‘
`
`-_ —
`
`—_
`
`109
`
`10000%
`
`9
`
`10000%
`
`100400%
`
`10000%
`
`Gene Name (Microarray)
`
`
`
`Gene
`ADA
`AR
`ASNS
`ASNS
`BRCA1
`BRCA2
`CD52
`CDW52
`CES2
`CES2*
`DCK
`DHFR
`DMNT1
`DMNT3A
`DMNT3B
`EGFR
`EPHA2
`ERBB2
`ESRI
`FLT1
`GART
`GNRH1
`HIF1A
`HSP90AA1
`HSPCA
`[L2RA
`KDR
`KIT
`LCK
`MGMT
`MLH1
`MSH2
`NFKBI
`NFKB2
`NFKB 1A
`PD GFC
`PD GFRA
`PD GFRB
`PGR
`PTEN
`PTGS2
`RARA
`RRM1
`RRM2
`RRM2B
`RXRG
`SPARC
`SPARC*
`SRC
`SSTRI
`SSTR2
`SSTR3
`SSTR4
`SSTR5
`TOP1
`TOP2A
`TOP2B
`TYMS
`VDR
`VEGF
`VEGFA
`VHL
`YES 1
`ZAP7
` Total Number of DMA
`Biomarkers Flagged as
`Talget for Tumor Type:
`Samoles
`
`
`
`94444100
`# of times
`biomarker
`flagged as
`target
`42
`27
`
`5 9
`
`62
`1
`
`21
`
`30
`18
`
`28
`
`13
`4
`
`FIG. 27B
`
`Bone if you have it
`if not Cartilage (1)
`# of times
`biomarker
`flagged as
`target
`
`# of times
`biomarker
`flagged as
`target
`000%
`0
`0.00%) ——
`
`Blood Vessel Vain (4)
`# of times
`biomarker
`flagged as
`target
`2
`
`4.359
`
`# of times
`biomarker
`flagged as
`target
`
`7.41%
`
`Bladder (7)
`
`# of times
`biomarker
`flagged as
`
`0
`
`1
`5
`
`10
`29
`18
`22
`
`15
`
`77
`
`12
`23
`
`4
`6
`2
`
`56
`1
`31
`33
`21
`55
`
`15
`
`48
`10
`1
`15
`
`4
`48
`15
`2
`16
`
`32
`42
`12
`74
`27
`23
`26
`34
`18
`29
`67
`1
`15
`
`11
`
`1
`
`6
`1
`2
`2
`
`1
`2
`
`2
`
`
`
`
`
`
`
`2.233;»
`333:?"
`—1133%? ==— 0.00%
`1 —~0 ——~°
`~
`9
`3.70%
`000%
`0
`0.00%
`0.00%) —
`000A)
`0.00% — 00% ——0‘004y 0.00% — 000%
`0.00% — 000g) ——0~004y° 000% — 0.00%
`0.00% — 0.00% — ~
`0°
`‘
`0
`0.00%
`—000A3 0.00%) —
`0.00% — 0001f) — 000%
`0.00% — 0.00%
`000% — 000? — 0‘009"
`000% — 0.00%
`”3%
`6524’ —— ‘°
`000%
`000A)
`0.00%) —
`0.00% — 0001f) — 000%
`0.00% — 0.00%
`617% — 000? — 0‘009"
`000% — 0.00%
`0.00% — 0.00% — ~
`0°
`‘
`0
`0.00%
`—000A3 9.0% —
`4.33% — 0.00% — ~
`0
`9099
`6.67%
`1
`3.70%)
`1
`4.94% — 0.000%) — a
`—0009
`3.33%
`2
`7.41%)
`.
`0
`370%
`6524’ —— °
`333%
`1
`000A)
`0.00%) —
`1.23% — 00% ——0‘004y 0.00%
`333%
`3.47% — 000g) ——0~004y° 000% — 0.00%
`0.00% — 0.00% — ~
`0°
`‘
`0
`0.00%
`—000A3 0.00%) —
`0.00% — 0.00% — ~
`0
`0009
`6.67%
`2
`7.41%)
`000% — 000? — 0009
`909%
`6.67%
`1
`494%
`”74’ —— ‘°
`000%
`000A)
`0.00%) —
`0.00% — 00% ——0‘004y1
`9.09%
`667%
`741%
`“7? — 0‘009"
`000% — 0.00%
`“7% — 0‘00? —— ‘
`°
`000%
`000A)
`0.00%) —
`0.00% — 0001f) — 000V
`000% — 0.00%
`1
`0.00% — 000g) — ~
`°
`000% — 0.00%
`000%
`”74’ —— °
`000%
`000A)
`0.00%) —
`0.00% — 0001f) — 000V
`000% — 0.00%
`0.00% — 0.00% — .
`04
`9090
`3.33%
`2
`7.41%)
`1
`”1% — 0‘00? —— °
`000%
`000A)
`0.00%) —
`1.23% — 0.001%) — 000%
`0.00% — 0.00%
`000% — 000? — 0‘009"
`000%
`3.33%
`247%
`87004 — ‘
`9°
`—0‘009
`333%
`2
`7.41%)
`.
`0
`0.00%
`6.522) — a
`9099
`3.33%
`2
`7.41%)
`2.47%
`6.521%) — 000V
`000% — 0.00%
`000% — 0‘00? —— ‘
`°
`667%
`2
`000A)
`0.00%) —
`0.00%
`217(4) ——0‘004y1
`9.09%
`667%
`000%
`435? — 0‘009"
`000% — 0.00%
`0.00% — 0.000%) — ~
`0°
`‘
`0
`0.00%
`—000A3 0.00%) —
`1.23% — 0004; — ~
`0
`000W — 0.00%
`2
`7.41%)
`2.47%
`2.171%) — 000V
`000% — 0.00%
`0.00% — 0.00% — ~
`0°
`‘
`0
`0.00%
`—000A3 0.00%) —
`0.00% — 0001f) — 000V
`000% — 0.00%
`000%
`“7? — ‘
`9"
`000% — 0.00%
`1
`3.70%)
`0.00% — 0.00% — 0
`0
`0.00%
`—000A3 0.00%) —
`0.00% — 0.00% — ~
`0
`9099
`6.67%
`1
`3.70%)
`1
`2.47%
`6.521%) — 000V
`000% — 0.00%
`0.00% — 0.00% — ~
`0°
`‘
`0
`0.00%
`—000A3 0.00%) —
`0.00%
`6521?) — 000V
`000% — 0.00%
`247% — 000? — ‘
`9"
`—000%— 0.00%
`2
`2
`7.41%)
`.
`0
`000%
`43504 — o
`0009 — 0.00%
`1
`3.70%)
`617%
`6‘52? — 0009
`0.00% — 0.00%
`5
`247% — 000? — 0‘009"
`000%
`3.33%
`2
`000% — 00004 — ‘
`9°
`0009
`3.33%
`1
`3.70%)
`8.64%
`4.351%) — 000V
`000% — 0.00%
`7
`7.41%
`2.17? — ~
`0°
`90W
`3.33%
`6
`2
`7.41%)
`1
`“7% — 0‘00? —— °
`000%
`2
`000A)
`0.00%) —
`0.00% — 00% ——0‘004y1
`9.09%
`667%
`4.94% — 0.001%) — 0‘00;
`000% — 0.00%
`4
`000% — 00004 — ‘
`9°
`—0‘009
`667%
`2
`7.41%)
`.
`0
`123%
`6‘52? — 0009
`0.00% — 0.00%
`1
`123% — 000? — 0‘009"
`000% — 0.00%
`1
`1.23%
`4354 — ~
`0°
`0‘000 — 0.00%
`1
`0
`0.00% — 0.00%)
`,
`N334403331000029 11
`1000043100009
`
`04444045)
`
`4.84%
`0 00%
`1.61%
`0.00%
`1 61%
`0 00%
`0.00%
`0.00%
`1 61%
`0 00%
`4.84%
`1.61%
`1 61%
`0 00%
`3.23%
`1.61%
`0.00%
`0 00%
`0.00%
`0.00%
`3.23%
`0 00%
`6 45%
`1.61%
`1.61%
`0 00%
`0 00%
`3.23%
`0.00%
`4 84%
`0 00%
`0.00%
`1.61%
`3 23%
`4 84%
`0.00%
`1.61A
`4.84%
`0 00%
`0.00%
`4.84%
`0.00%
`0 00%
`0 00%
`0.00%
`0.00%
`4 84%
`0 00%
`1.61%
`1.61%
`0 00%
`4.84
`1.61%
`4.84%
`0 00%
`1 61%
`3.23%
`0.00%
`8.06%
`0 00%
`1.61%
`1.61%
`0.00%
`0 00%
`100.00'
`
`# of times
`biomarker
`flagged as
`
`r—w—‘w
`
`r—‘N
`
`r—‘r—‘Jk
`
`>—‘N>—‘
`
`W W
`
`W N
`
`3.63%
`2.33%
`0.43%
`0.00%
`0 78%
`5 35%
`0.09%
`0.00%
`1 81%
`0 00%
`2.59%
`1.55%
`0.17
`0 69%
`1.12%
`0.35%
`0.00%
`0.86%
`2.50%
`1.55%
`1.90%
`0 00%
`1 30%
`0.60%
`0.60%
`0 00%
`1 04%
`1.99%
`0.00%
`4.84%
`0.09%
`2.68%
`2.85%
`1.81%
`4.75%
`0.09%
`0.43%
`4.15%
`0.86%
`0.09%
`1.30%
`0.00%
`0 35%
`4 15%
`1.30%
`0.17%
`1 38%
`0 00%
`2.76%
`3.63%
`1.04%
`6.39%
`2.33%
`1.99%
`2.25%
`2.94%
`1.55%
`2.50%
`5.79%
`0.09%
`1.30%
`0.00%
`0.95%
`0 00%
`100.00' 0
`
`1158
`
`82
`
`
`
`FIG. 27C
`
`Dendritic cells can be
`found in skin, the spleen,
`lymph node. Let’s get
`Difficult origin to define.
`Mike Bittner’s take on site
`Endometrium (3)
`Try skeletal muscle (1)
`of origin (1)
`Colon Sigmoid (1)
`Colon (66)
`Cervix (10)
`# of times
`# of times
`# of times
`# of times
`# of times
`# of times
`biomarker
`biomarker
`biomarker
`biomarker
`biomarker
`biomarker
`biomarker
`flagged as
`flagged as
`flagged as
`flagged as
`flagged as
`flagged as
`flagged as
`target
`target
`target
`target
`target
`target
`target
`—————————————
`—————————————
`—————————————
`—————————————
`—————————————
`—————————————
`—————————————
`—————————————
`—————————————
`—————————————
`—————————————
`—————————————
`—————————————
`————————————-_
`u———————————-_
`———————————-—
`—————————————
`—————————————
`—————————————
`—————————————
`—————————————
`—————————————
`—————————————
`—————————————
`—————————————
`—————————————
`———————-_—————
`—————————————
`—————————————
`————————————-
`—————————————
`—————————————
`—————————————
`—————————-———
`———————————